A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria

The antimalarial drug DSM265 displays activity against blood and liver stages of Plasmodium falciparum and has a long predicted half-life in humans. Long-acting new treatment for drug-resistant malaria Malaria kills 0.6 million people annually, yet current malaria drugs are no longer fully effective because the parasite that causes malaria is becoming resistant to these agents. Phillips et al. have identified a new drug that kills both drug-sensitive and drug-resistant malaria parasites by targeting the ability of the parasite to synthesize the nucleotide precursors required for synthesis of DNA and RNA. This drug kills parasites in both the blood and liver and is sufficiently long-acting that it is expected to cure malaria after a single dose or to be effective if dosed weekly for chemoprevention. Malaria is one of the most significant causes of childhood mortality, but disease control efforts are threatened by resistance of the Plasmodium parasite to current therapies. Continued progress in combating malaria requires development of new, easy to administer drug combinations with broad-ranging activity against all manifestations of the disease. DSM265, a triazolopyrimidine-based inhibitor of the pyrimidine biosynthetic enzyme dihydroorotate dehydrogenase (DHODH), is the first DHODH inhibitor to reach clinical development for treatment of malaria. We describe studies profiling the biological activity, pharmacological and pharmacokinetic properties, and safety of DSM265, which supported its advancement to human trials. DSM265 is highly selective toward DHODH of the malaria parasite Plasmodium, efficacious against both blood and liver stages of P. falciparum, and active against drug-resistant parasite isolates. Favorable pharmacokinetic properties of DSM265 are predicted to provide therapeutic concentrations for more than 8 days after a single oral dose in the range of 200 to 400 mg. DSM265 was well tolerated in repeat-dose and cardiovascular safety studies in mice and dogs, was not mutagenic, and was inactive against panels of human enzymes/receptors. The excellent safety profile, blood- and liver-stage activity, and predicted long half-life in humans position DSM265 as a new potential drug combination partner for either single-dose treatment or once-weekly chemoprevention. DSM265 has advantages over current treatment options that are dosed daily or are inactive against the parasite liver stage.

[1]  Bill Bynum,et al.  Lancet , 2015, The Lancet.

[2]  David W. Gray,et al.  A novel multiple-stage antimalarial agent that inhibits protein synthesis , 2015, Nature.

[3]  D. Ménard,et al.  Towards real-time monitoring of artemisinin resistance. , 2015, The Lancet. Infectious diseases.

[4]  Hongshen Ma,et al.  (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium , 2014, Proceedings of the National Academy of Sciences.

[5]  Baldur P Magnusson,et al.  A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Imidazolopiperazine KAF156 To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers , 2014, Antimicrobial Agents and Chemotherapy.

[6]  Baldur P Magnusson,et al.  A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Antimalarial Spiroindolone KAE609 (Cipargamin) To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers , 2014, Antimicrobial Agents and Chemotherapy.

[7]  Baldur P Magnusson,et al.  Spiroindolone KAE609 for falciparum and vivax malaria. , 2014, The New England journal of medicine.

[8]  K. Kuhen,et al.  KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission , 2014, Antimicrobial Agents and Chemotherapy.

[9]  Jeremy N. Burrows,et al.  Fluorine Modulates Species Selectivity in the Triazolopyrimidine Class of Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors , 2014, Journal of medicinal chemistry.

[10]  D. Wirth,et al.  In Vitro Resistance Selections for Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors Give Mutants with Multiple Point Mutations in the Drug-binding Site and Altered Growth , 2014, The Journal of Biological Chemistry.

[11]  R. Price,et al.  Single-dose radical cure of Plasmodium vivax: a step closer , 2014, The Lancet.

[12]  V. Barton,et al.  Novel inhibitors of the Plasmodium falciparum electron transport chain , 2014, Parasitology.

[13]  K. Kuhen,et al.  KAI407, a Potent Non-8-Aminoquinoline Compound That Kills Plasmodium cynomolgi Early Dormant Liver Stage Parasites In Vitro , 2013, Antimicrobial Agents and Chemotherapy.

[14]  David M. Shackleford,et al.  In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models , 2013, Drug design, development and therapy.

[15]  V. Avery,et al.  Identification of inhibitors of Plasmodium falciparum gametocyte development , 2013, Malaria Journal.

[16]  B. Tekwani,et al.  Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicity , 2013, Proceedings of the National Academy of Sciences.

[17]  Nancy Fullman,et al.  The changing epidemiology of malaria elimination: new strategies for new challenges , 2013, The Lancet.

[18]  Silvia Parapini,et al.  A Plasmodium falciparum screening assay for anti-gametocyte drugs based on parasite lactate dehydrogenase detection. , 2013, The Journal of antimicrobial chemotherapy.

[19]  D. Leroy,et al.  Antimalarial drug discovery – the path towards eradication , 2013, Parasitology.

[20]  Anne E Carpenter,et al.  A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. , 2013, Cell host & microbe.

[21]  P. Conaghan,et al.  Safety evaluation of leflunomide in rheumatoid arthritis , 2013, Expert opinion on drug safety.

[22]  J. Burrows,et al.  Designing the next generation of medicines for malaria control and eradication , 2013, Malaria Journal.

[23]  Jennifer L. Guler,et al.  Asexual Populations of the Human Malaria Parasite, Plasmodium falciparum, Use a Two-Step Genomic Strategy to Acquire Accurate, Beneficial DNA Amplifications , 2013, PLoS pathogens.

[24]  R. Sinden,et al.  Male and Female Plasmodium falciparum Mature Gametocytes Show Different Responses to Antimalarial Drugs , 2013, Antimicrobial Agents and Chemotherapy.

[25]  Yuexin Li,et al.  Quinolone-3-Diarylethers: A New Class of Antimalarial Drug , 2013, Science Translational Medicine.

[26]  X. Su,et al.  Malaria biology and disease pathogenesis: insights for new treatments , 2013, Nature Medicine.

[27]  Yongyuth Yuthavong,et al.  Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target , 2012, Proceedings of the National Academy of Sciences.

[28]  R. Sinden,et al.  A high-throughput assay for the identification of malarial transmission-blocking drugs and vaccines. , 2012, International journal for parasitology.

[29]  J. Burrows,et al.  The global pipeline of new medicines for the control and elimination of malaria , 2012, Malaria Journal.

[30]  Xavier C Ding,et al.  A framework for assessing the risk of resistance for anti-malarials in development , 2012, Malaria Journal.

[31]  Xavier C Ding,et al.  A framework for assessing the risk of resistance for antimalarials in development , 2012, Malaria Journal.

[32]  S. Duparc,et al.  Optimal dose finding for novel antimalarial combination therapy* , 2012, Tropical medicine & international health : TM & IH.

[33]  Jeremy N. Burrows,et al.  P. falciparum In Vitro Killing Rates Allow to Discriminate between Different Antimalarial Mode-of-Action , 2012, PloS one.

[34]  E. Winzeler,et al.  The Activities of Current Antimalarial Drugs on the Life Cycle Stages of Plasmodium: A Comparative Study with Human and Rodent Parasites , 2012, PLoS medicine.

[35]  D. Fidock,et al.  Identifying apicoplast‐targeting antimalarials using high‐throughput compatible approaches , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  David M. Shackleford,et al.  Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. , 2011, Journal of medicinal chemistry.

[37]  David M. Shackleford,et al.  Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. , 2011, Journal of medicinal chemistry.

[38]  A. Thomas,et al.  Towards an In Vitro Model of Plasmodium Hypnozoites Suitable for Drug Discovery , 2011, PloS one.

[39]  Philip R. Evans,et al.  An introduction to data reduction: space-group determination, scaling and intensity statistics , 2011, Acta crystallographica. Section D, Biological crystallography.

[40]  D A Smith,et al.  The use of C(av) rather than AUC in safety assessment. , 2010, Regulatory toxicology and pharmacology : RTP.

[41]  Pradipsinh K Rathod,et al.  Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. , 2010, Infectious disorders drug targets.

[42]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[43]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[44]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[45]  Werner Kaminsky,et al.  Structural Plasticity of Malaria Dihydroorotate Dehydrogenase Allows Selective Binding of Diverse Chemical Scaffolds* , 2009, The Journal of Biological Chemistry.

[46]  L. Shultz,et al.  Improved Murine Model of Malaria Using Plasmodium falciparum Competent Strains and Non-Myelodepleted NOD-scid IL2Rγnull Mice Engrafted with Human Erythrocytes , 2009, Antimicrobial Agents and Chemotherapy.

[47]  P. Rathod,et al.  Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum. , 2008, Journal of medicinal chemistry.

[48]  J. Dressman,et al.  Dissolution Media Simulating Conditions in the Proximal Human Gastrointestinal Tract: An Update , 2008, Pharmaceutical Research.

[49]  P. Rathod,et al.  Analysis of flavin oxidation and electron-transfer inhibition in Plasmodium falciparum dihydroorotate dehydrogenase. , 2008, Biochemistry.

[50]  Hua-rong Lu,et al.  In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. , 2007, European journal of pharmacology.

[51]  D. Roden,et al.  On the relationship among QT interval, atrial fibrillation, and torsade de pointes. , 2007, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[52]  J. Chollet,et al.  In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. , 2007, Experimental parasitology.

[53]  D. Roden,et al.  When should QT be measured? Summer solstice or Christmas Eve? , 2007, Heart rhythm.

[54]  Hua-rong Lu,et al.  In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. , 2006, European journal of pharmacology.

[55]  Airlie J. McCoy,et al.  Solving structures of protein complexes by molecular replacement with Phaser , 2006, Acta crystallographica. Section D, Biological crystallography.

[56]  P. Kowey,et al.  Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. , 2006, Heart rhythm.

[57]  P. Rathod,et al.  High-throughput Screening for Potent and Selective Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase* , 2005, Journal of Biological Chemistry.

[58]  Qingcheng Mao,et al.  Role of the breast cancer resistance protein (ABCG2) in drug transport , 2005, The AAPS Journal.

[59]  D. Warhurst,et al.  Modified Fixed-Ratio Isobologram Method for Studying In Vitro Interactions between Atovaquone and Proguanil or Dihydroartemisinin against Drug-Resistant Strains of Plasmodium falciparum , 2004, Antimicrobial Agents and Chemotherapy.

[60]  Christian Scheurer,et al.  Identification of an antimalarial synthetic trioxolane drug development candidate , 2004, Nature.

[61]  P. Augustijns,et al.  Apricot extract inhibits the P-gp-mediated efflux of talinolol. , 2002, Journal of pharmaceutical sciences.

[62]  G Beck,et al.  Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. , 2001, Journal of pharmaceutical sciences.

[63]  R. Brent.  The history of the editorship of Teratology during the period from July 1, 1976 to January 1, 1993. , 2001, Teratology.

[64]  E. Zeiger,et al.  The Ames Salmonella/microsome mutagenicity assay. , 2000, Mutation research.

[65]  K. Mortelmans,et al.  The bacterial tryptophan reverse mutation assay with Escherichia coli WP2. , 2000, Mutation research.

[66]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[67]  X. Su,et al.  Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum. , 2002, Molecular pharmacology.

[68]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.

[69]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.